Singapore, 6 June 2023 - Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ...
CDC: Mycobacterium abscessus is a bacterium distantly related to the ones that cause tuberculosis and leprosy.It is part of a group of environmental mycobacteria and is found in water, soil, and dust.
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for ...
Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% About AN2 Therapeutics, Inc. AN2 ...
Three patients developed difficult-to-treat Mycobacterium abscessus infections after receiving embryonic stem cell injections in Mexico in 2022, researchers reported. Two men -- one from Colorado and ...
(RTTNews) - AN2 Therapeutics Inc. (ANTX) announced that the U.S. FDA has cleared its investigator-initiated trial evaluating Epetraborole in 90 patients with Mycobacterium abscessus lung disease, ...
Background. Mycobacterium abscessus and Mycobacterium massiliense, which cause lung disease, are variable in their clinical manifestation and progression. We hypothesized that mycobacterial genotypes ...
A female patient with cystic fibrosis in her mid-twenties has a positive AFB sputum culture. Below is a Kinyoun stain of positive MGIT tube fluid. The images show branching, beaded bacterial rods that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results